Home/Pipeline/ABS-101

ABS-101

Inflammatory Bowel Disease (IBD)

Pre-clinicalActive (Published research)

Key Facts

Indication

Inflammatory Bowel Disease (IBD)

Phase

Pre-clinical

Status

Active (Published research)

Company

AbSci

About AbSci

Absci is on a mission to create better biologics for patients, faster, by unlocking novel biology with generative AI. Founded in 2011, the company has built a unique 'lab-in-the-loop' platform that iterates between generating massive proprietary datasets, training AI models for de novo design and optimization, and validating millions of designs weekly in its wet lab. With over 25 programs in its partnered and internal pipeline, including a lead candidate for androgenetic alopecia, Absci is positioning itself as a leader in the AI-driven biotherapeutics space.

View full company profile

Therapeutic Areas

Dermatology Immunology Inflammatory Diseases Oncology

Other Inflammatory Bowel Disease (IBD) Drugs

Drug	Company	Phase	Status
DFTX-201	Definium Therapeutics	Preclinical	Lead Optimization
COSMO-232	Cosmo Pharmaceuticals	Preclinical	Active
Tamuzimod	Ventyx Biosciences	Phase 2	Completed
VTX958	Ventyx Biosciences	Phase 2	Completed
GPR35 Agonist	Nxera Pharma	Preclinical	Active
SL-325	Shattuck Labs	Phase 2	Active
SL-425	Shattuck Labs	Phase 1	Active
Metabolite Delivery Platform (Therapeutic Programs)	ClostraBio	Pre-clinical	Platform Development
ABO21009	AboleIIs Pharma	Phase 1	Planned/Preclinical